Janssen: New Subgroup Analysis of the Phase 3 OPTIMUM Study

Early treatment in multiple sclerosis (MS) with higher-potency therapies can improve long-term patient outcomes1,2 New subgroup analysis of the pivotal Phase 3 OPTIMUM trial shows that MS patients

Related Keywords

Janssen Cilag Gm , Alexandra Nisipeanu , Jennifer Mcintyre , Prinzj Ponesimod , Janssen Cilag International , None Of The Janssen Pharmaceutical Companies , European Commission , National Multiple Sclerosis Society , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Actelion Pharmaceuticals Ltd , Exchange Commission , Janssen Global Services , Companies Of Johnson , Idorsia Pharmaceuticals Ltd , Johnson , European Committee , Treatment Research , Multiple Sclerosis , About Multiple Sclerosis , Pharmaceutical Companies , Cardiovascular Metabolism , Infectious Diseases Vaccines , Janssen Cilag , Concerning Forward Looking Statements , Private Securities Litigation Reform Act , Janssen Pharmaceutica , Annual Report , Note Regarding Forward Looking , Quarterly Report , Scler Relat , Adv Chronic , Once Daily , Moral Therapy , Relapsing Forms , Active Disease Defined , Janssen , Subgroup , Analysis , Hase , Optimum , Study , Emonstrates , Benefits , Onvorytm , Onesimod , Dover , Teriflunomide , Early , Disease , Multiple , Clerosis ,